Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia

Steven P. Treon, Shayna Sarosiek, Jorge J. Castillo

Blood (2024) 143 (17): 1702–1712.

https://doi.org/10.1182/blood.2022017235

Published: 2024

Journal Articles

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Jorge J. Castillo, Andrew R. Branagan, David Sermer, Catherine A. Flynn, Kirsten Meid, Megan Little, Katherine Stockman, Timothy White, Alexa Canning, Maria L. Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nicholas Tsakmaklis, Christopher J. Patterson, Zachary R. Hunter, Steven P. Treon, Shayna Sarosiek

Blood (2024) 143 (7): 582–591.

https://doi.org/10.1182/blood.2023022420

Published: 2024

Includes: Supplemental data

Journal Articles

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Blood (2022) 140 (Supplement 1): 1549–1550.

https://doi.org/10.1182/blood-2022-169863

Published: 2022

Journal Articles

Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

Jorge J. Castillo, Shayna Sarosiek, Andrew R. Branagan, David J. Sermer, Catherine A. Flynn, Carly Leventoff, Megan Little, Timothy P White, Kirsten Meid, Alexa Canning, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P Treon

Blood (2022) 140 (Supplement 1): 564–565.

https://doi.org/10.1182/blood-2022-155610

Published: 2022

Journal Articles

Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia

Blood (2022) 140 (Supplement 1): 3541–3542.

https://doi.org/10.1182/blood-2022-170254

Published: 2022

Journal Articles

Skin Punch Biopsy Findings in Patients with IgM MGUS and Waldenström Macroglobulinemia Presenting with Peripheral Neuropathy

Shayna Sarosiek, Helmut G Rennke, Catherine A. Flynn, Christopher T Doughty, Andrew R. Branagan, Steven P Treon, Jorge J. Castillo

Blood (2022) 140 (Supplement 1): 6507–6508.

https://doi.org/10.1182/blood-2022-169977

Published: 2022

Journal Articles

Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression

Blood (2022) 140 (Supplement 1): 1740–1741.

https://doi.org/10.1182/blood-2022-170412

Published: 2022

Journal Articles

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Blood (2022) 140 (Supplement 1): 10094–10096.

https://doi.org/10.1182/blood-2022-167899

Published: 2022

Journal Articles

A New Role for the SRC Family Member HCK As a Driver of BCR/SYK Signaling in MYD88 Mutated Lymphomas

Blood (2021) 138 (Supplement 1): 3512.

https://doi.org/10.1182/blood-2021-153610

Published: 2021

Journal Articles

The ERK1/2 Regulator WNK2 Shows Differential Expression and Isoform Usage, Primarily Driven By Aberrant Methylation, in MYD88 Mutated Waldenström's Macroglobulinemia

Maria Luisa Guerrera, Guang Yang, Xia Liu, Nickolas Tsakmaklis, Maria G Demos, Amanda Kofides, Manit Munshi, Lian Xu, Christopher J Patterson, Jorge J. Castillo, Shayna Sarosiek, Catherine A Flynn, Kirsten Meid, Joshua Gustine, Tomasz Sewastianik, Ruben D. Carrasco, Steven P Treon, Zachary R Hunter

Blood (2021) 138 (Supplement 1): 2692.

https://doi.org/10.1182/blood-2021-154160

Published: 2021

Journal Articles

Interim Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

Christopher Dittus, Matthew J Weinstock, Jeffrey A Barnes, Jose Sandoval-Sus, Xianming Tan, Xinyi Zhang, Areej El-Jawahri, Shayna Sarosiek, John Mark Sloan

Blood (2021) 138 (Supplement 1): 1395.

https://doi.org/10.1182/blood-2021-144422

Published: 2021

Journal Articles

Dose Reductions Related to Adverse Effects in Patients with Waldenström Macroglobulinemia Treated with the BTK-Inhibitor Ibrutinib

Shayna Sarosiek, Joshua Gustine, Catherine A Flynn, Carly Leventoff, Timothy P White, Kirsten Meid, Steven P Treon, Jorge J. Castillo

Blood (2021) 138 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2021-154284

Published: 2021

Journal Articles

Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations

Manit Munshi, Xia Liu, Amanda Kofides, Nickolas Tsakmaklis, Joshua Gustine, Shayna Sarosiek, Catherine A Flynn, Kirsten Meid, Timothy P White, Carly Leventoff, Christopher J Patterson, Andrew R. Branagan, Prafulla Gokhale, Michael J Poitras, Zachary R Hunter, Maria Luisa Guerrera, Jorge J. Castillo, Guang Yang, Steven P Treon

Blood (2021) 138 (Supplement 1): 2261.

https://doi.org/10.1182/blood-2021-153856

Published: 2021

Journal Articles

COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Blood (2021) 138 (Supplement 1): 3801.

https://doi.org/10.1182/blood-2021-154089

Published: 2021

Journal Articles

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

Charles J. Milrod, Frances Blevins, David Hughes, Adam Lerner, Shayna Sarosiek, Vaishali Sanchorawala, J. Mark Sloan

Blood (2021) 137 (21): 2987–2989.

https://doi.org/10.1182/blood.2021010853

Published: 2021

Includes: Supplemental data

Journal Articles

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

David Hughes, PharmD, Radhika Jhaveri, PharmD, Bhavesh Shah, RPh, Frances Blevins, PA-C, Alexamil Rodriguez, CPhT, Shayna Sarosiek, MD, Adam Lerner, MD, John Mark Sloan, MD, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-135992

Published: 2020

Journal Articles

Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications

Frances Blevins, PA-C, David Hughes, PharmD, Charles Milrod, MD, Preya Patel, MD, Shayna DeMari, BA, Adam Lerner, MD, Shayna Sarosiek, MD, Vaishali Sanchorawala, MD, John Mark Sloan, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136775

Published: 2020

Journal Articles

Early Serum Free Light Chain Response after High-Dose Melphalan and Stem Cell Transplantation Predicts Hematologic Response in AL Amyloidosis

Vanessa Fiorini Furtado, MD, Dina Brauneis, ANP, Shayna Sarosiek, MD, Karen Quillen, MDMPH, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-138500

Published: 2020

Journal Articles

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Terri L. Parker, MD, Adam Rosenthal, MS, Vaishali Sanchorawala, MD, Heather J Landau, MD, Erica Campagnaro, MD, Prashant Kapoor, MD, Natalia Neparidze, MD, Patrick Hagen, MD, Shayna Sarosiek, MD, Emma C. Scott, MD, Antje Hoering, PhD, Brian G.M. Durie, MD, Saad Z. Usmani, MDMBBS,MBA, Robert Z. Orlowski, MDPhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-143180

Published: 2020

Journal Articles

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

Vaishali Sanchorawala, Shayna Sarosiek, Amanda Schulman, Meredith Mistark, Mary Ellen Migre, Ramon Cruz, J. Mark Sloan, Dina Brauneis, Anthony C. Shelton

Blood (2020) 135 (18): 1541–1547.

https://doi.org/10.1182/blood.2019004436

Published: 2020

NARROW

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia

Skin Punch Biopsy Findings in Patients with IgM MGUS and Waldenström Macroglobulinemia Presenting with Peripheral Neuropathy

Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression

Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

A New Role for the SRC Family Member HCK As a Driver of BCR/SYK Signaling in MYD88 Mutated Lymphomas

The ERK1/2 Regulator WNK2 Shows Differential Expression and Isoform Usage, Primarily Driven By Aberrant Methylation, in MYD88 Mutated Waldenström's Macroglobulinemia

Interim Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

Dose Reductions Related to Adverse Effects in Patients with Waldenström Macroglobulinemia Treated with the BTK-Inhibitor Ibrutinib

Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations

COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications

Early Serum Free Light Chain Response after High-Dose Melphalan and Stem Cell Transplantation Predicts Hematologic Response in AL Amyloidosis

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only